|
FY2016
12 months to Dec 31, 2016
|
FY2015
12 months to Dec 31, 2015
|
FY2014
12 months to Dec 31, 2014
|
FY2013
12 months to Dec 31, 2013
|
FY2012
12 months to Dec 31, 2012
|
|
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of products sold | |||||
| Amortization of acquired inventory step-up | |||||
| Gross profit | |||||
| Operating expenses: | |||||
| Selling, general and administrative | |||||
| Research, development and other technology | |||||
| Medical device excise tax | |||||
| Acquisition transaction, integration and legal costs | |||||
| Intangible asset amortization | |||||
| Contingent consideration expense | |||||
| Reduction in fair value of contingent consideration liability | |||||
| Intangible asset impairment | |||||
| Total operating expenses | |||||
| Operating loss | |||||
| Other expense: | |||||
| Interest expense | |||||
| Foreign currency transaction loss | |||||
| Other income, net | |||||
| Total other expense | |||||
| Loss before income taxes | |||||
| Income tax expense (benefit) | |||||
| Net loss | |||||
| Net loss per share: | |||||
| Net loss per share, basic and diluted (in usd per share) | |||||
| Other comprehensive loss, net of tax | |||||
| Foreign currency translation adjustments, net of tax | |||||
| Comprehensive loss, net of tax | |||||
| Weighted average common shares outstanding: | |||||
| Diluted (in shares) | |||||
| Basic and diluted (in shares) | |||||
Loading...